Literature DB >> 21589950

The role of inflammation and infection in prostate cancer: Importance in prevention, diagnosis and treatment.

H K Koul1, B Kumar, S Koul, A A Deb, J S Hwa, P Maroni, A van Bokhoven, M S Lucia, F J Kim, R B Meacham.   

Abstract

It is currently estimated that infections and inflammatory responses are linked to 15-20% of all deaths from cancer worldwide. Many studies point to an important role of inflammation in prostate growth, although the contribution of inflammation to benign prostatic hyperplasia and prostate cancer is not completely understood. There is an unmet need for epidemiologic and molecular pathologic approaches to address the issue of inflammation and prostate cancer. Here we review the published evidence with respect to the involvement of inflammation and infection in prostate cancer. We also present an overarching hypothesis that chronic inflammation associated with aging and infection may play an important role in the etiology and progression of prostate cancer. As such, chronic inflammation may represent an important therapeutic target in prostate cancer. Copyright 2010 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21589950     DOI: 10.1358/dot.2010.46.12.1537942

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  9 in total

1.  Protective effect of γ-tocopherol-enriched diet on N-methyl-N-nitrosourea-induced epithelial dysplasia in rat ventral prostate.

Authors:  Lucas D Sanches; Sergio A A Santos; Jaqueline R Carvalho; Gabriela D M Jeronimo; Wagner J Favaro; Maria D G Reis; Sérgio L Felisbino; Luis A Justulin
Journal:  Int J Exp Pathol       Date:  2013-10-29       Impact factor: 1.925

2.  Temporal changes in the pathologic assessment of prostate cancer.

Authors:  M Scott Lucia; Adrie van Bokhoven
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

3.  Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia.

Authors:  Shinji Ohtake; Takashi Kawahara; Yukari Ishiguro; Teppei Takeshima; Shinnosuke Kuroda; Koji Izumi; Hiroshi Miyamoto; Hiroji Uemura
Journal:  Mol Clin Oncol       Date:  2018-07-03

Review 4.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

5.  Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1.

Authors:  Rajnee Kanwal; Mitali Pandey; Natarajan Bhaskaran; Gregory T Maclennan; Pingfu Fu; Lee E Ponsky; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2012-07-25       Impact factor: 4.784

6.  SM22α suppresses cytokine-induced inflammation and the transcription of NF-κB inducing kinase (Nik) by modulating SRF transcriptional activity in vascular smooth muscle cells.

Authors:  Xiaohua Dai; Devi Thiagarajan; Jingye Fang; Jianbin Shen; Neeraja Priyanka Annam; Zhao Yang; Hong Jiang; Donghong Ju; Youming Xie; Kezhong Zhang; Yan Yuan Tseng; Zhe Yang; Arun K Rishi; Hui J Li; Maozhou Yang; Li Li
Journal:  PLoS One       Date:  2017-12-28       Impact factor: 3.240

Review 7.  Main Inflammatory Cells and Potentials of Anti-Inflammatory Agents in Prostate Cancer.

Authors:  Takuji Hayashi; Kazutoshi Fujita; Makoto Matsushita; Norio Nonomura
Journal:  Cancers (Basel)       Date:  2019-08-12       Impact factor: 6.639

8.  A novel pathway links oxidative stress to loss of insulin growth factor-2 (IGF2) imprinting through NF-κB activation.

Authors:  Bing Yang; Jennifer Wagner; Nathan Damaschke; Tianyu Yao; Shelly M Wuerzberger-Davis; Moon-Hee Lee; John Svaren; Shigeki Miyamoto; David F Jarrard
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

9.  Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer.

Authors:  Parvin Forghani; Mohammad R Khorramizadeh; Edmund K Waller
Journal:  Cancer Med       Date:  2014-01-20       Impact factor: 4.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.